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Key Points
• Iron deficiency may
explain the association
between RDW and risk
of VTE.
•Contrary to the hypoth-
esis, increasing plasma
levels of hepcidin, a
biomarker of iron
stores, were associated
with increased risk of
VTE.
Red cell distribution width (RDW) is associated with venous thromboembolism (VTE), but
the underlying mechanism(s) is unclear. Iron deficiency is associated with high RDW, and
studies suggest an association between iron deficiency and VTE. To assess whether iron
deficiency is a risk factor for VTE that explains the association between RDW and VTE, we
conducted a nested case-control study of 390 patientswith VTE and 802 age- and sex-matched
controls selected from the population-based cohort of the Tromsø Study. Physical
measurements and blood samples were collected from 1994 to 1995. Logistic regression
models were used to calculate odds ratios (ORs) with 95% confidence intervals (CIs) for
VTE by RDW, hepcidin, and ferritin light chain (FtL). RDW was inversely associated with
hepcidin, FtL, and hemoglobin. The risk of VTE increased linearly across categories of
higher plasma hepcidin levels. Participants with hepcidin in the highest quartile had an
OR for VTE of 1.32 (95% CI, 1.00-2.42), and those in the .90% percentile had an OR for
VTE of 1.66 (95% CI, 1.14-2.42) compared with the reference group (quartiles 2 and 3).
The risk estimates remained similar after adjustment for C-reactive protein. The risk of
VTE increased by categories of higher RDW and was strengthened after inclusion of
hepcidin and FtL in the multivariable model. Our findings reject the hypothesis that iron
deficiency explains the association between RDW and VTE and suggest, in contrast, that
high body iron levels might increase the risk of VTE.
Introduction
Venous thromboembolism (VTE) is a collective term for deep vein thrombosis (DVT) and pulmonary
embolism (PE). VTE is a complex disease affecting 1 to 2 per 1000 individuals each year,1,2 with serious
short- and long-term complications.3,4 In contrast to arterial cardiovascular diseases, such as myocardial
infarction and ischemic stroke, where incidence has declined by 25% to 50% over the last 2 decades,5
the incidence of VTE has slightly increased during this time period.6,7 It is assumed that the incidence of
VTE will continue to rise in the coming years because the prevalence of major risk factors for VTE,8-10
such as older age, obesity, and cancer, is increasing in the population.8,11,12 VTE has become a major
challenge to public health and health care systems because of associated frequent hospitalizations,
monitoring of treatment to avoid bleeding complications, severe complications, and a high mortality
rate.13 To diminish the health burden of VTE, it is crucial to identify novel biomarkers and unravel
underlying disease mechanisms, which may improve risk prediction and guide decisions on targeted
prevention and treatment.
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Red cell distribution width (RDW) has in recent years been associated
with several diseases,14 including VTE,15-17 but the underlying
mechanisms remain unknown. RDW is traditionally used in a classi-
fication system for anemia,18 and iron deficiency anemia is strongly
associated with high RDW.19,20 Moreover, iron deficiency anemia has
been associated with risk of incident VTE,21 VTE recurrence,22 PE,23
and cerebral venous thrombosis.24 However, iron deficiency anemia
may have several causes, which may act as confounders for the
association between iron deficiency and VTE.25 Therefore, whereas
the association between iron deficiency and high RDW as well as the
association between high RDW and VTE risk seems well established,
the association between iron deficiency and VTE remains to be proven.
Assessment of body iron stores is challenging, especially in healthy
individuals.26 The human body has no known active iron excretion,
and intestinal iron absorption and macrophage iron recycling regulate
iron homeostasis.27 Hepcidin has, since its discovery in 2001,
been identified as a key regulator of iron metabolism.28 Ferroportin
transports iron from duodenal enterocytes, macrophages, and hepa-
tocytes to plasma and is the only known iron exporter in humans.29
Hepcidin causes endocytosis and degradation of ferroportin, resulting
in a rapid decrease in plasma iron.30 Additionally, hepcidin might inhibit
apical iron uptake in enterocytes.31 Hepcidin expression is regulated by
iron availability, inflammatory cytokines, and erythropoietic demand.28,32
Iron deficiency results in a swift reduction in hepcidin levels,33 and
hepcidin might be a useful biomarker of iron deficiency in healthy
individuals.34 Ferritin light chain (FtL), part of the major iron metabolism
protein ferritin, is especially important for iron uptake and storage,35
and FtL is less sensitive to inflammation than ferritin.36
The aims of the present nested case-control study with participants
recruited from a population-based cohort were: to investigate whether
iron deficiency, assessed by hepcidin and FtL, was associated with risk
of VTE and to investigate whether the apparent association between
RDW and VTE could be explained by underlying iron deficiency as
assessed by these markers.
Material and methods
Study population
The Tromsø Study is a single-center prospective cohort study with
repeated health surveys of the inhabitants of the municipality of Tromsø,
Norway.37 The fourth survey was conducted from 1994 to 1995, and all
inhabitants age$25 years were invited to participate. A total of 27 158
individuals participated (77% of those invited) and were followed from
the date of inclusion until an incident VTE, migration, death, or end of
follow-up (1 September 2007). All first lifetime VTE events were
identified using the hospital discharge diagnosis registry, the autopsy
registry, and the radiology procedure registry from University Hospital of
North Norway, which is the sole hospital in the Tromsø region. Trained
personnel confirmed and recorded each VTE by extensive medical
record review, as previously described.38 A VTE was confirmed if
presence of signs and symptoms of PE or DVT were combined with
objective confirmation by a diagnostic procedure (ie, compression
ultrasonography, venography, spiral computed tomography, perfusion-
ventilation scan, pulmonary angiography, or autopsy), resulting in
treatment initiation (unless contraindications were specified). The VTEs
were classified as PE with or without concurrent DVT or as DVT only.
During the follow-up period (1994-2007), 462 individuals experienced a
VTE event. For each VTE case, 2 age-, sex-, and index date–matched
controls were selected (n 5 924). The index date was defined as the
date of the VTE event, meaning that the controls had to be alive and
without a VTE diagnosis at the time of the VTE event in the
corresponding case. For 45 cases and 75 controls, plasma samples
of sufficient quality for the analyses were unavailable. Moreover, 5
individuals were excluded because of missing values for hepcidin, FtL,
or RDW. Finally, participants with a cancer diagnosis before (n5 57) or
within 1 year from the inclusion date (n5 12) were excluded, because
active or occult cancer might have influenced the hepcidin and/or FtL
levels. In total, 390 VTE cases and 802 controls were included in our
study. The regional committee of medical and health research ethics
approved the study, and all participants provided written consent.
Measurements
Physical measurements and blood samples were collected from
1994 to 1995. Height and weight were measured with participants
wearing light clothes and no shoes. Body mass index (BMI) was
calculated as weight in kilograms divided by the square of height in
meters (kg/m2). Information on smoking habits was obtained from
self-administered questionnaires. For measurement of blood-cell
variables (including RDW), 5 mL of blood was drawn from an
antecubital vein into a vacutainer tube containing EDTA as an
anticoagulant and analyzed within 12 hours in an automated blood-
cell counter (Coulter Counter; Coulter Electronics, Luton, United
Kingdom). RDW was calculated by dividing the standard deviation
(SD) of mean corpuscular volume by mean cell volume and multiplying
by 100 to express the result as a percentage.20 Serum and citrated
plasma were prepared by centrifugation (2000 3 g for 15 minutes)
after 1-hour respite at room temperature and frozen at270°C. Plasma
samples were thawed, and enzyme-linked immunosorbent assays were
used to measure levels of hepcidin (catalog #DY8307-05; R&D
Systems, Stillwater, MN), FtL (catalog #H00002512-AP49 and
recombinant protein H00002512-P01; Abnova, Taipei, Taiwan), and
C-reactive protein (CRP; catalog #DY1707; R&D Systems) in a
384 format using a combination of a CyBi SELMA (CyBio, Jena,
Germany), EL406 washer/dispenser (Biotek, Winooski, VT), and
Synergy H2 microplate reader (Biotek). The intra- and interassay
coefficients of variation were ,10% for all assays.
Statistical analyses
Statistical analyses were performed with STATA software (version
14.0; Stata Corporation, College Station, TX). Participants were
categorized into quartiles based on the distribution of baseline
hepcidin, FtL, and RDW among the control population. Extra cutoff
points were established at the 10th and 90th percentiles, respectively.
Pearson’s correlation coefficients were estimated for RDW,
hepcidin, FtL, hemoglobin, and CRP. Unconditional logistic re-
gression models were used to calculate odds ratios (ORs) with
95% confidence intervals (CIs) for VTE by hepcidin, FtL, and RDW
modeled as continuous and categorical variables. Quartiles 2 and 3
(ie, 25th-75th percentiles) were combined and used as a reference
group in the categorical analysis. The multivariable model included
age, sex, BMI, and CRP. For the analysis of VTE risk by RDW,
hepcidin and FtL were included in an extra multivariable model.
Results
Baseline characteristics and correlations
Among the 390 VTE cases, 42.6% (n 5 166) were unprovoked
events, and 38.7% (n 5 151) were diagnosed with a PE (Table 1).
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In general, there were only minor differences between the case and
control groups. Patients with VTE had slightly higher BMI, and a
slightly higher proportion were men, whereas the proportion of
smokers and participants with anemia was higher in the control
group. CRP, hemoglobin, and platelet levels were similar in cases
and controls (Table 1).
The correlations between the studied markers are shown in Table 2
and supplemental Figure 1. RDWwas inversely correlated with plasma
levels of hepcidin, FtL, and hemoglobin and positively correlated with
plasma CRP. As expected, hepcidin correlated positively with FtL and
hemoglobin, and FtL correlated with hemoglobin. In contrast to the
correlation with RDW, only weak correlations were found between
CRP and hepcidin and between CRP and FtL.
Association of hepcidin and FtL and future risk of VTE
The risk of VTE increased with higher plasma levels of hepcidin
(Table 3). In crude analysis, study participants with hepcidin in the
highest quartile had a 32% higher risk of VTE than those with
hepcidin in the 2 middle quartiles (OR, 1.32; 95% CI, 1.00-2.42).
The risk estimates increased further for participants with hepcidin
.90th percentile, with an OR of 1.66 (95% CI, 1.14-2.42).
Moreover, a trend toward a lower risk of VTE with lower hepcidin
levels was noted. Participants with hepcidin in the lower quartile had
an OR for VTE of 0.92 (95% CI, 0.67-1.25) compared with the
reference group, whereas those with hepcidin levels ,10th
percentile had an OR of 0.82 (95% CI, 0.52-1.29). Adjustment
for age, sex, BMI, and CRP did not significantly alter the risk
estimates. In the linear model, 1 SD increase in hepcidin was
associated with a 17% higher risk of VTE (OR, 1.17; 95% CI, 1.04-
1.31). The risk estimate was essentially similar in the fully adjusted
model (OR, 1.15; 95% CI, 1.02-1.30).
Similar, although less pronounced and not statistically significant,
results were found for FtL, with increased risk of VTE by higher
plasma levels of FtL and a modest trend toward decreased risk of
VTE by lower levels of FtL (Table 3). Compared with the reference
group, participants with FtL in the highest quartile had a 1.1-fold
increased risk of VTE (OR, 1.10; 95% CI, 0.82-1.47), and those
with FtL levels .90th percentile had an OR of 1.21 (95% CI, 0.81-
1.80). The risk estimates were attenuated in the multivariate model,
with ORs of 1.01 and 1.11, respectively. In the linear model, 1 SD
increase in FtL yielded an OR for VTE of 1.10 (95% CI, 0.99-1.22),
and the risk estimate was slightly attenuated in the multivariable
model (OR, 1.06; 95% CI, 0.95-1.19).
Association of RDW and future risk of VTE with and
without adjustment for hepcidin and FtL
In accordance with previous findings, the risk of VTE increased with
categories of higher RDW (Table 4). Individuals with RDW in the
upper quartile had 46% higher odds of VTE (OR, 1.46; 95% CI,
1.11-1.93) compared with the reference group. Adjusting for age,
sex, BMI, and CRP did not alter the risk estimates. Further
adjustment for hepcidin and FtL strengthened the risk estimates
slightly (fully adjusted OR, 1.58; 95% CI, 1.18-2.11).
Discussion
In this nested case-control study, we investigated whether iron
deficiency was a risk factor for VTE that could explain the
association between RDW and VTE. However, we found a dose-
dependent association between plasma levels of hepcidin and risk
of VTE that was independent of CRP. Similar, although not
statistically significant, results were found for FtL. Our results
suggest that high body iron stores may increase the risk of VTE. In
agreement with previous studies,16,17 we demonstrated a dose-
response relationship between RDW and risk of VTE. Adjusting for
hepcidin and FtL increased rather than reduced the risk estimates
for VTE by RDW, suggesting that these parameters may, at least
partly, reflect different pathways in VTE development. Therefore, it is
unlikely that the association between RDW and VTE is explained by
underlying iron deficiency.
In contrast to our findings, a history of iron deficiency anemia was
associated with VTE in a case-control study including 2522 patients
with VTE and 12 610 randomly selected controls from Taiwan.21
The OR for previous iron deficiency anemia was 1.43 (95% CI,
1.10-1.87) for patients with VTE compared with controls. Possible
confounders, such as malignancy and inflammatory bowel disease,
were included in the multivariable model. However, information on
treatment was not available. Because both oral and IV iron therapies
may induce oxidative stress,39 the observed association could have
been driven by the use of iron supplements among patients with
VTE with a history of iron deficiency. To explore the effect of iron
deficiency on the risk of VTE recurrence, Potaczeck et al22
Table 1. Characteristics of VTE cases and controls
Characteristic VTE Cases (n 5 390) Controls (n 5 802)
Age, y 59.8 6 13.9 59.7 6 13.8
Male sex 48.5 (189) 47.4 (380)
BMI, kg/m2 27.1 6 4.6 26.0 6 4.1
Smoker 30.8 (120) 32.3 (262)
Hemoglobin, g/dL 14.3 6 1.2 14.1 6 1.1
Trc, 3109/L 246.9 6 56.1 244.1 6 52.5
RDW, % 13.2 6 1.1 13.0 6 0.8
Hepcidin, ng/mL 55.9 6 36.6 50.2 6 33.5
FtL, ng/mL 11.2 6 12.4 9.9 6 10.0
CRP, mg/L 1.7 6 1.4 1.6 6 1.4
Anemia* 2.1 (8) 4.2 (33)
Unprovoked VTE 42.6 (166) —
PE 38.7 (151) —
DVT 61.3 (239) —
Values are means 6 1 SD or percentages with absolute numbers in parentheses.
Trc, thrombocyte.
*Anemia defined as hemoglobin levels ,12.0 g/dL in women and ,13.0 g/dL in men.
Table 2. Correlation matrix for RDW, hepcidin, FtL, hemoglobin, and
CRP
RDW Hepcidin FtL Hemoglobin CRP
RDW 1.00
Hepcidin 20.17* 1.00
FtL 20.11* 0.50* 1.00
Hemoglobin 20.17* 0.15* 0.25* 1.00
CRP 0.12* 0.08* 0.09* 0.08* 1.00
*P , .05.
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conducted a prospective study of 229 patients with incident,
unprovoked VTE. The exclusion criteria included, among others, iron
administration, known cancer, and chronic inflammatory diseases.
The authors did not report the number of patients with a VTE
recurrence during follow-up, but the 24-month recurrence-free
survival probability was 89.5%. Patients with iron deficiency (n5 47),
defined as serum ferritin levels ,30 mg/L, had a threefold increased
risk of VTE recurrence compared with patients without iron deficiency
(n 5 182) during a mean follow-up of 13 months. The association
was independent of CRP levels. However, the study sample was
relatively small, the definition of iron deficiency may be questionable,
and the findings in patients with VTE are not necessarily applicable to
a predominantly healthy population.
Iron is an essential trace element required for several crucial
physiologic functions. However, excess free iron is toxic. Humans
have no known regulated pathway for iron excretion, and iron
balance is maintained by the tight regulation of iron absorption from
the intestine. When the amount of iron in the body decreases, the
iron uptake must increase and vice versa.30,40 Growing evidence
suggests hepcidin is the primary regulator of iron stores. Hepcidin
gene expression is induced by iron loading and suppressed by
anemia and hypoxia,28 and it is a promising tool in assessing iron
status.34,41 Moreover, hepcidin gene expression is induced by
inflammatory processes, and hepcidin is suggested to be the driver
of anemia in chronic diseases.32 To date, ferritin is among the most
used measurements of iron status.26 However, its ability to assess
iron stores is reduced in individuals without anemia,42 and the
interpretation of ferritin values is challenging in the presence of
concurrent inflammation.43 Ferritin consists of 2 subunits, FtL and
ferritin heavy chain. FtL is especially important for iron uptake and
storage35 and is less sensitive to inflammation than ferritin heavy
chain,36 and the combined use of hepcidin and FtL, as in the
present study, may be an accurate tool to define iron deficiency.
In contrast to our hypothesis and previous studies, our results
suggest that high body iron levels increase the risk of VTE. The
underlying mechanism(s) is unclear, but the relationship between iron
and oxidative stress may contribute to the association. Both oral and
IV iron therapies may induce oxidative and nitrosative stress.39
Chronic iron dextran administration (15 mg over 6 weeks) was
associated with accelerated thrombus formation after photochemical
carotid artery injury in mice,44 and administration of a reactive oxygen
species scavenger revoked the effect. Excess iron-induced oxidative
Table 3. ORs with 95% CIs for VTE by categories and per SD of hepcidin and FtL
Percentile Range, ng/mL VTE cases, n Controls, n OR (95% CI)* OR (95% CI)† OR (95% CI)‡
Hepcidin
,10th 2.0-10.2 30 80 0.82 (0.52-1.29) 0.84 (0.53-1.34) 0.84 (0.53-1.34)
,25th 2.0-22.0 84 200 0.92 (0.67-1.25) 0.93 (0.67-1.27) 0.93 (0.68-1.28)
25th-75th 22.0-65.2 184 401 Referent Referent Referent
.75th 65.2-192.0 122 201 1.32 (1.00-1.76) 1.29 (0.97-1.72) 1.27 (0.95-1.70)
.90th 95.9-192.0 61 80 1.66 (1.14-2.42) 1.62 (1.11-2.37) 1.61 (1.10-2.37)
Per 1 SD increase — — — 1.17 (1.04-1.31) 1.16 (1.03-1.30) 1.15 (1.03-1.30)
FtL
,10th 0.3-2.0 37 80 0.95 (0.62-1.46) 0.91 (0.59-1.41) 0.92 (0.59-1.42)
,25th 0.3-3.8 88 200 0.91 (0.67-1.23) 0.93 (0.68-1.27) 0.93 (0.68-1.39)
25th-75th 3.8-11.9 195 402 Referent Referent Referent
.75th 11.9-108.9 107 200 1.10 (0.82-1.47) 1.04 (0.77-1.41) 1.03 (0.76-1.39)
.90th 18.4-108.9 47 80 1.21 (0.81-1.80) 1.17 (0.77-1.76) 1.13 (0.75-1.71)
Per 1 SD increase — — — 1.10 (0.99-1.22) 1.08 (0.97-1.21) 1.08 (0.96-1.21)
*Model 1: crude OR.
†Model 2: adjusted for age, sex, and BMI.
‡Model 3: model 2 plus CRP.
Table 4. ORs with 95% CIs for VTE by categories and per SD of RDW
Percentile Range, % VTE cases, n Controls, n OR (95% CI)* OR (95% CI)† OR (95% CI)‡
,10th 11.2-12.2 29 73 0.90 (0.56-1.42) 0.92 (0.58-1.48) 0.89 (0.56-1.44)
,25th 11.2-12.5 71 178 0.90 (0.65-1.24) 0.94 (0.67-1.31) 0.92 (0.66-1.29)
25th-75th 12.5-13.3 185 417 Referent Referent Referent
.75th 13.3-20.1 134 207 1.46 (1.11-1.93) 1.48 (1.11-1.97) 1.58 (1.18-2.11)
.90th 13.9-20.1 68 99 1.55 (1.09-2.21) 1.53 (1.06-2.19) 1.66 (1.15-2.41)
Per 1 SD increase — — — 1.24 (1.11-1.38) 1.23 (1.10-1.37) 1.28 (1.14-1.44)
*Model 1: crude OR.
†Model 2: adjusted for age, sex, BMI, and CRP.
‡Model 3: model 2 plus hepcidin and FtL.
1194 ELLINGSEN et al 12 JUNE 2018 x VOLUME 2, NUMBER 11
.For personal use onlyon December 20, 2018. by guest  www.bloodadvances.orgFrom 
stress may also decrease nitric oxide bioavailability and cause
endothelial dysfunction and platelet activation.45,46 Fibrinogen is
particularly susceptible to oxidation, and exposure of fibrinogen to
Fe31 promotes fibrin formation, enhances platelet aggregation,
and supports less efficient plasminogen activation by tissue-type
plasminogen activator.47,48 Although there was an association
between high hepcidin levels and risk of VTE, we cannot necessarily
conclude that these individuals had iron excess. Nonetheless, it is
tempting to hypothesize that this association reflects a pathogenic
link between iron and oxidative stress that could promote VTE.
Major strengths of our study are the clear temporal sequence
between exposure and outcome, the large number of participants
recruited from a general population, and the well-validated VTE
events. Some limitations merit consideration. The biological
properties of hepcidin and FtL are well described, and there is a
good biological rationale for their role in iron metabolism.28-33,35
However, their role in assessment of body iron stores among
healthy individuals remains to be evaluated in relation to a gold
standard (ie, stainable bone marrow iron). The analyses of hepcidin,
FtL, and CRP were performed in blood samples drawn from 1994
to 1995 and stored at 270°C for up to 23 years. This long storage
time could potentially have influenced the plasma levels of hepcidin,
FtL, and CRP. Samples stored at 270°C for long periods have
displayed a minor lowering in serum levels of hepcidin,49 but it is
unlikely that this would affect the risk of VTE as long as the expected
storage effect were similar in all study participants. Moreover, the
median time from blood sampling to a VTE event was 7 years, and
the individual levels of hepcidin and/or FtL might have changed
during this period. A modifiable risk factor may introduce mis-
classification because of the long time from blood sampling to
outcome. This type of nondifferential misclassification generally
leads to underestimation of the true association.50 Moreover, the
observed association between hepcidin and VTE might have been
confounded by underlying inflammation. Among 51 critically ill
patients with anemia, the sensitivity of hepcidin for detection of iron
deficiency was only 50%,51 and hepcidin was a poor predictor of
bone marrow iron deficiency in 207 anemic children with high
incidence of acute or chronic infections.52 Nevertheless, inclusion
of CRP in the multivariable model did not attenuate our results
significantly, and CRP was only weakly correlated with hepcidin and
FtL. Various medications and dietary supplements may influence
iron metabolism, as may underlying conditions such as heart failure
or inflammatory conditions. Unfortunately, we did not have baseline
information on these conditions, and therefore, it is not possible to
rule out residual confounding by unrecognized or unmeasured
factors in the present study.
In conclusion, we found a dose-response relationship between
plasma levels of hepcidin and risk of VTE. These results suggest
that iron deficiency is not a risk factor for VTE and cannot explain the
association between RDW and VTE. In contrast, our findings
suggest that high body iron stores (ie, iron stores in the upper part
of normal values) are associated with increased risk of incident VTE
in a general, initially cancer-free, population. Future studies should
confirm our findings and investigate underlying mechanisms for the
effect of high iron stores on future risk of VTE.
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